Canaccord Genuity Group Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CF.TO | CANG | INVP.L | BGC | CS0.F | 1776.HK | |
|---|---|---|---|---|---|---|
| Market cap | 1.38B | 74.66M | 3.73B | 5.50B | 9.15B | 125.75B |
| P/E (TTM) | — | — | 7.9 | 29.5 | 6.6 | 6.3 |
| Forward P/E | 9.5 | -13.0 | 6.1 | 7.4 | — | 6.7 |
| Price/book | 2.4 | 0.6 | 0.9 | 5.0 | 0.8 | 0.8 |
| Dividend yield | 2.94% | — | 6.50% | 0.67% | 3.48% | 5.52% |
| 1-year change | +15.13% | −91.14% | +1.63% | +26.09% | −21.77% | −18.28% |
| Today | −0.95% | −23.21% | +0.59% | −0.84% | +2.61% | +2.68% |
The closest companies by business and industry (Capital Markets). Prices may be delayed up to 15 min.
Latest news
All CF.TO news ›Canaccord Genuity Sticks to Their Buy Rating for Incyte (INCY)
In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Incyte, with a price target of $152.00. According to TipRanks, Newman is an analyst with an average return of -2.8% and a 39.11% success rate. Newman…
Canaccord Genuity Keeps Their Buy Rating on Voyager Therapeutics (VYGR)
Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating on Voyager Therapeutics yesterday and set a price target of $12.00. The company’s shares closed yesterday at $3.20. Kulkarni covers the Healthcare sector, focusing on stocks…
EL Maintains by Canaccord Genuity -- Price Target Raised to $109
On October 19, 2026, Estee Lauder Cos EL received a rating update from Canaccord Genuity, which maintained a 'Hold' rating while increasing the price target from $90.00 to $109.00, reflecting a 21.11% change. The GF Score™ is a…
Canaccord Genuity Adjusts Price Target on Estee Lauder Companies to $109 From $90
Published on 10/22/2026 at 07:37 am EDT Estée Lauder Stages a Comeback August 20, 2026 at 09:02 am EDT Moderna Surges on Cancer Vaccine; Estee Lauder Rallies on Earnings | Stock Movers Luxury: when Chinese consumers choose face cream over…
PensionBee Group (LON:PBEE) Earns Buy Rating from Canaccord Genuity Group
Posted by Kim Johansen on Oct 22nd, 2026 PensionBee Group (LON:PBEE – Get Free Report)‘s stock had its “buy” rating reiterated by Canaccord Genuity Group in a research report issued to clients and investors on Thursday, Digital Look…
Afentra (LON:AET) Given “Buy” Rating at Canaccord Genuity Group
Afentra (LON:AET – Get Free Report)‘s stock had its “buy” rating restated by Canaccord Genuity Group in a report issued on Wednesday, Digital Look reports. They presently have a GBX 135 price objective on the stock. Canaccord Genuity…
Canaccord Genuity Upgrades Bellevue Gold to Buy from Speculative Buy; Price Target is AU$1.75
Bellevue Gold has an average rating of buy and mean price target of AU$1.74, according to analysts polled by FactSet. ... Canaccord Genuity Upgrades Bellevue Gold to Buy from Speculative Buy; Price Target is AU$1.75 Published on 07/29/2026…
Canaccord Genuity Keeps Their Buy Rating on Actinogen Medical (ATGGF)
In a report released yesterday, Shane Storey from Canaccord Genuity maintained a Buy rating on Actinogen Medical , with a price target of A$0.08. According to TipRanks, Storey is a 3-star analyst with an average return of 2.2% and a 46.88%…
Quoin Pharmaceuticals (NASDAQ:QNRX) Now Covered by Canaccord Genuity Group
Posted by Mitch Edgeman on Oct 20th, 2026 Canaccord Genuity Group started coverage on shares of Quoin Pharmaceuticals (NASDAQ:QNRX – Free Report) in a research report sent to investors on Monday, MarketBeat.com reports. The firm issued a…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
themarketsdaily.com22
-
defenseworld.net17
-
marketbeat.com11
-
marketscreener.com7
-
theglobeandmail.com5
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 74 articles, not a forecast.